報價延遲最少15分鐘:2025/04/12 19:42 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
18.205 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-26.75/-9.38
|
|
企業價值
189.13M
|
| 資產負債 |
|
每股賬面淨值
14.91
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.28M
|
|
每股收益
5.16
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/12 19:42 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases. |